Lung (includes NSCLC, SCLC, Mesothelioma)

Phase III IMpower150 Study Showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) Plus Chemotherapy Significantly Reduced The Risk Of Disease Worsening Or Death In The Initial Treatment Of People With A Type Of Advanced Lung Cancer

(Roche) Nov 20, 2017 - Roche today announced that the Phase III IMpower150 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) compared to Avastin plus chemotherapy in the first-line treatment of people with advanced non-squamous non-small cell lung cancer (NSCLC).

read corporate press release

Roche Win Boosts Case For Adding Chemo To Cancer Immunotherapy

(Reuters) Nov 20, 2017 - Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier scepticism.

read article

New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases

(Yahoo! Finance) Nov 19, 2017 - AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

read article

Osimertinib Improves Progression-free Survival in Asian EGFR-mutated Lung Cancer Patients

(ESMO Asia 2017 Congress) Nov 18, 2017 - Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset analysis of the FLAURA trial presented at the ESMO Asia 2017 Congress, simultaneously published in The New England Journal of Medicine.

read press release

ALEX Study Shows Alectinib 600 Mg More Effective Than Crizotinib In Asian Lung Cancer Patients

(ESMO Asia 2017 Congress) Nov 17, 2017 - A subanalysis of the phase III ALEX study has shown that alectinib (1) 600 mg twice daily is more effective than standard of care crizotinib in Asian patients with anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer (NSCLC), researchers report at the ESMO Asia 2017 Congress.

read press release

Lung Cancer Triggers Pulmonary Hypertension

(Max Planck Institute [Bad Nauheim, Germany]) Nov 17, 2017 - Nearly half of all advanced-stage lung cancer patients develop arterial pulmonary hypertension.

read article

AstraZeneca to Present Transformative Data at ESMO Asia 2017 Congress from Pivotal Trials Showing Potential New Standards of Care in Non-small Cell Lung Cancer

(Yahoo! Finance) Nov 17, 2017 - At the ESMO Asia 2017 Congress in Singapore, 17-19 November 2017, AstraZeneca and MedImmune, its global biologics research and development arm, will share ground-breaking results from two pivotal trials, as well as new data from the FLAURA trial on central nervous system (CNS) metastases in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) and subset data in Asian patients.

read article

LUNGevity Partners with ALK Positive Patient Group to Fund Lifesaving Research

(Yahoo! Finance) Nov 15, 2017 - LUNGevity Foundation is honored to announce that it is partnering with the ALK Positive patient group to support the new ALK-Positive Lung Cancer Transformational Research Award Program.

read article

Mirati Therapeutics Announces Advancement Of First-In-Class Opportunities With Sitravatinib And KRAS Inhibitor Programs

(Mirati) Nov 13, 2017 - Sitravatinib immuno-oncology program to be accelerated following encouraging clinical efficacy data previously reported for sitravatinib in combination with nivolumab; KRAS program advances with orally-active, mutation-selective clinical lead and backups; IND submission anticipated in 2018.

read corporate press release

Phase III Trial With Zepsyre® In Small-Cell Lung Cancer (ATLANTIS) To Continue On The Basis Of Positive Recommendation By IDMC

(PharmaMar) Nov 15, 2017 - PharmaMar has announced today that the Independent Data Monitoring Committee (IDMC) has notified the Company of its recommendation that the Phase III (ATLANTIS) trial currently underway with Zepsyre® (PM1183) in combination with doxorubicin in small-cell lung cancer patients should continue without any changes.

read corporate press release

Lung Cancer May Grow Faster During Immunotherapy

(Medscape Medical News) Nov 13, 2017 - A retrospective analysis from France found that 14% of patients with advanced lung cancer showed an acceleration of tumor growth while receiving immunotherapy.

read article (free registration required)

Nektar Therapeutics' Stock Rockets Toward Near 17-Year High After Upbeat Trial Data

(MarketWatch) Nov 13, 2017 - The company said Saturday that data from the Pivot-02 phase 1/2 study, designed to evaluate the combination of Bristol-Myers Squibb Co.'s Opdivo with its investigational medicine NKTR-214, demonstrated "important" response rates across the three types of tumors tested.

read article

First Data For NKTR-214 In Combination With OPDIVO® (Nivolumab) For Patients With Stage IV Melanoma, Renal Cell Carcinoma And Non-Small Cell Lung Cancers, Including Patients With PD-L1 Negative Status, Revealed At SITC 2017

(Nektar Therapeutics) Nov 11, 2017 - Interim data from the dose-escalation phase of the PIVOT-02 trial highlighted as an oral presentation.

read corporate press release

Will a Boom In Genetic Testing Of Tumors Be A Boon For Soon-Shiung?

(STAT Plus) Nov 13, 2017 - Cancer patients across the country are increasingly being tested for “microsatellite instability,” or MSI status — a genetic marker that can help doctors identify the most effective treatment.

read article (paid subscription required)

Does Gut Flora Impact the Response to Cancer Immunotherapy?

(MedPage Today) Nov 7, 2017 - Gut microbes can help or hinder cancer patients' response to immunotherapy, two new studies suggested.

read article (free registration required)

Initial Results from Phase 2 Study of CB-839 in Combination with Opdivo® (nivolumab) to be Presented at the Society for Immunotherapy of Cancer Meeting

(Calithera Biosciences) Nov 7, 2017 - Calithera Biosciences, Inc. today announced that initial data from the ongoing trial of CB-839 in combination with Opdivo® in patients with melanoma, renal cell carcinoma and non-small cell lung cancer will be presented Saturday, November 11th, 2017, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.

read corporate press release

Pique Therapeutics Announces Positive Results in Phase 2 Clinical Trial of Lead Immunotherapy for Non-Small Cell Lung Cancer

(Business Insider) Nov 7, 2017 - Pique Therapeutics, Inc. today announced positive results for PT 107 from its Phase 2 clinical trial in patients with late-stage, second-line non-small cell lung cancer (NSCLC).

read article

Takeda Recognizes ALK+ Day with Launch of tALK+ Initiative During November’s Lung Cancer Awareness Month

(biotech-365) Nov 8, 2017 - tALK+ promotes the insights, contributions and individuals making a positive impact on the forefronts of ALK+ non-small cell lung cancer (NSCLC); launch of ALKConnect Registry connects and informs patients living with ALK+ NSCLC.

read article

FDA Approves Roche Drugs For Rare Types Of Blood, Lung Cancers

(Reuters) Nov 6, 2017 - Roche Holding AG won U.S. approval to market its skin cancer drug Zelboraf for certain patients with Erdheim-Chester Disease, a rare type of blood cancer, and to market its drug Alecensa as a first choice of treatment for a subset of patients with non-small cell lung cancer.

read article

FDA Approves Roche’s Alecensa (Alectinib) As First-Line Treatment For People With Specific Type Of Lung Cancer

(Roche) Nov 7, 2017 - Roche today announced that the US Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Alecensa® (alectinib) for the treatment of people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

read corporate press release
Next Page